About Us
Pentixapharm is a radiopharmaceutical development company founded in 2019, with its headquarters in Würzburg, Germany. It is committed to develop the innovative theranostic pair PentixaFor and PentixaTher, two small peptide-based radiopharmaceuticals that specifically target the CXCR4-receptor expressed in hematological and solid cancers, as well as cardiovascular and endocrine diseases.
Our Team
Pentixapharm's team consists of 40 employees, 22 with PhDs, with a high level of qualification and expertise. This team has extensive experience from previous roles at leading firms and institutions such as Bayer, Novartis, Octreopharm, Roche, Parexel, Charité, Universität Würzburg, MDC, and LMU Munich. Their collective achievements include involvement in three drug approvals, conducting several Phase III and Phase I/II trials, six investigator-initiated studies, and participation in over 35 clinical trials, demonstrating a robust track record in the pharmaceutical industry.
Meet our Core Team
-
Dr. Hakim Bouterfa
CEO & Co-Founder
-
Anna Steeger
CFO & Co-Founder
-
Dr. Dirk Pleimes
CSO & CMO
-
Dr. Simone Pickel
Senior Clinical Research Manager
-
Dr. Anna Janz
Senior Clinical Research Manager
-
Dr. Juan Castillo
Senior CMC Manager
-
Dr. Kerstin Ott
Medical Affairs
-
Dr. Alessandra Bierwagen
Regulatory Affairs
-
Dr. Aylin Cankaya
CMC
-
Dr. Neydher Berroterán-Infante
CMC Director
-
Melissa Nahm
Scientific Coordinator for Business Development
-
Phillip Eckert
Market Access